**Thursday, September 7, 2017**

**Mount Zion Boutique Hotel - Jerusalem**

|  |  |
| --- | --- |
| 08:15 - 08:45 | KENOTE LECTURE – **Fragile X Associated Primary Ovarian Insufficiency: A Leading Edge in a Paradigm Shift”**. *Dr. Lawrence Nelson, Director, Strategic Alliances, Mary Elizabeth Conover Foundation, Inc., McLean, VA.* |
| 08:45 - 10:15 | **SESSION:** FRAGILE X-ASSOCIATED PRIMARY OVARIAN INSUFFICIENCY, REGESTATIONAL DIAGNOSIS, AND SCREENING |
|  | CGG repeat in the mid-range and the longer repeats after the last AGG interruption are correlated with poor ovarian reserve in FMR1 permutation patients. *L. Man, Weill Cornell Medicine, NY.* |
|  | Characterization and preliminary correction of the FXPOI phenotype in the 130-Repeat Fragile X premutation mouse. *J. Johnson, University of Colorado-Denver, Denver.* |
|  | The ovarian response in Fragile X patients and pre-mutation carriers undergoing IVF-PGD: Reappraisal. *S. Avraham, Lis Maternity Hospital, Tel Aviv Sourasky Medical Center.* |
|  | Twelve years' experience with PGD for Fragile X female carriers. *M. Malcov, Lis Maternity Hospital, Tel Aviv Sourasky Medical Center.* |
|  | Prenatal diagnosis of Fragile X: Can a full mutated FMR1 gene be contracted to a normal size? *E. Manor, Soroka University Medical Center, Beersheva.* |
|  | Both expanded CGG repeats and altered FMR protein can modulate the resting follicle pool in the mouse ovary. *K. Shelly, Baylor College of Medicine.*  |

|  |  |
| --- | --- |
| 10:15 – 10:45 | COFFEE BREAK |
| 10:45 – 12:30 | **SESSION** (continued) |
|  | Modifying factors may play a larger role among the most vulnerable mid-range premutation group of women. *EG. Allen, Emory University, Atlanta.* |
|  | Identifying modifying genes to explain the variation in severity of FMR1 premutation-associated disorders. *SL. Sherman, Emory University, Atlanta.*  |
|  | Determining “screen positive” cases in Fragile X newborn screening: Issues, dilemmas and options. *A. Wheeler, RTI International, RTP NC.*  |
|  | Carrier screening for Fragile X syndrome in Australia. *J Cohen, Genetic Clinics Australia.*  |
|  | AGG interruption as a risk factor of CGG repeat expansion and genetic consulting. *N. Domniz, Sheba Medical Center, Tel Hashomer.* |
|  | PGD vs CVS: Decision making among FMR1 premutation carriers wishing to conceive. *L. Marom, Sheba Medical Center, Tel Hashomer.* |
|  | To test or not to test? Premutation analysis in minors - ethical and medical dilemmas and consideration. *L. Gabis. Sheba Medical Center, Tel Hashomer.* |
| 12:30 – 13:00 | ROUND TABLE AND DISCUSSION |
| 13:00 – 14:00 | LUNCH |
| 14:00 – 15:30 | **SESSION:** ASSOCIATED FEATURES IN PREMUTATION CARRIERS |
|  | Endocrine and metabolic profile among Fragile X premutation women. *N.Gruber, Sheba Medical Center, Tel Hashomer.* |
|  | FMR1 premutation phenotype in population-based & clinically-ascertained women. *M. Mailick, University of Wisconsin Madison.* |
|  | Clinical and molecular correlates in Fragile X premutation females. *P. Jiraanont, UC Davis MIND Institute CA.* |
|  | Stress, coping, and mindfulness in women with an FMR1 premutation. *A. Wheeler, RTI International, RTP NC.* |
|  | Feasibility of a mindfulness intervention among women with an FMR1 premutation experiencing maternal stress. *J.E. Hunter, Kaiser Permanente Northwest, Portland.* |
|  | Is stress and anxiety in FMR1 premutation carriers in part related to parenting a child with a developmental disability? *N. Mc Devitt, Trinity College, the University of Dublin.* |
| 15:30 - 16:00 | COFFEE-BREAK |
| 16:00 - 17:00 | **SESSION** (continued) |
|  | Health knowledge among women with a fragile X premutation. *SL. Sherman, Emory University, Atlanta.*  |
|  | Sensory difficulties in children with the FMR1 premutation. *M. Raspa, RTI International, RTP NC.* |
|  | Negative affect in infants with the FMR1 premutation. *A. Wheeler, RTI International, RTP NC.* |
|  | Parent report of neurodevelopmental problems in an unbiased cohort of children with a premutation allele. *A. Glicksman, NYS Institute for Basic Research, Staten Island New York.* |
| 17:00 – 17:30 | ROUND TABLE AND FINAL DISCUSSION  |